ABSTRACT
There are currently about 257 million people suffering from chronic HBV infection worldwide. In many cases, an insufficient Tcell response is causative for establishment of a chronic infection. To ensure a robust cellular immune response and induction of neutralizing antibodies a novel vaccine platform based on modified cell-permeable HBV capsids was utilized. Cell permeability was achieved by fusion of the membrane-permeable TLM-peptide to HBV core monomers, assembling the capsids. Insertion of a Strep-tagIII into the spike tip domain that protrudes from the capsid surface enables flexible loading with antigens that are fused to streptavidin. In this study, HBV surface antigen-derived PreS1PreS2 domain, fused to monomeric streptavidin, served as cargo antigen. Binding between antigen and capsids was characterized by surface plasmon resonance spectroscopy, electron microscopy and density gradient centrifugation. Confocal immunofluorescence microscopy and in vivo imaging of immunized mice demonstrated membrane permeability of cargo-loaded carriers and spread of antigen over the whole organism. Immunization experiments of mice revealed a robust induction of a specific cellular immune response, leading to destruction of HBV-positive cells and induction of HBV-specific neutralizing antibodies. Membrane permeability of these carriers allows needle-free application of antigen-loaded capsids as evidenced by induction of an HBV-specific CTL response and HBV-specific B cell response after oral or transdermal vaccination. These data indicate that cell-permeable antigen carriers, based on HBV capsids and loaded with HBV antigen, have the capacity to induce a cellular and a neutralizing humoral immune response. In addition, cell permeability of the vaccine platform enables antigen transfer across several cell layers, that could allow oral or transdermal immunization.
Subject(s)
Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Hepatitis B, Chronic , Immunity, Cellular , Animals , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Vaccines/immunology , Hepatitis B, Chronic/prevention & control , Mice , VaccinationABSTRACT
Protein nanocages are promising multifunctional platforms for nanomedicine owing to the ability to decorate their surfaces with multiple functionalities through genetic and/or chemical modification to achieve desired properties for therapeutic and diagnostic purposes. Here, we describe a model antigen (OVA peptide) that was conjugated to the surface of a naturally occurring hepatitis B core protein nanocage (HBc NC) by genetic modification. The engineered OVA-HBc nanocages (OVA-HBc NCs), displaying high density repetitive array of epitopes in a limited space by self-assembling into symmetrical structure, not only can induce bone marrow derived dendritic cells (BMDC) maturation effectively but also can be enriched in the draining lymph nodes. Naïve C57BL/6 mice immunized with OVA-HBc NCs are able to generate significant and specific cytotoxic T lymphocyte (CTL) responses. Moreover, OVA-HBc NCs as a robust nanovaccine can trigger preventive antitumor immunity and significantly delay tumor growth. When combined with a low-dose chemotherapy drug (paclitaxel), OVA-HBc NCs could specifically inhibit progression of an established tumor. Our findings support HBc-based nanocages with modularity and scalability as an attractive nanoplatform for combination cancer immunotherapy.
Subject(s)
Antigens, Neoplasm/administration & dosage , Hepatitis B Core Antigens/immunology , Nanoconjugates/administration & dosage , Neoplasms/therapy , Animals , Antigens, Neoplasm/immunology , Bioengineering/methods , Cell Proliferation/drug effects , Dendritic Cells/drug effects , Dendritic Cells/immunology , Epitopes/genetics , Epitopes/immunology , Hepatitis B/immunology , Hepatitis B Core Antigens/administration & dosage , Humans , Immunotherapy/methods , Mice, Inbred C57BL , Neoplasms/immunology , T-Lymphocytes, Cytotoxic/drug effects , T-Lymphocytes, Cytotoxic/immunologyABSTRACT
Neisseria meningitidis caused meningitis is life-threatening acute infection with high fatality and high frequency of severe sequelae. Meningococcal capsular polysaccharides can be used to prevent meningococcal disease; while conjugating the polysaccharides to carrier protein was found necessary to improve the immunogenicity and induce memory responses in infants and young children. Nevertheless, repeated administration of glycoconjugate vaccines might lead to carrier-induced epitope suppression due to limited number of carrier proteins. Here in this study, full-length hepatitis B core antigen virus-like particles (HBc VLPs) was used as a novel potential carrier protein for conjugation of meningococcal group C polysaccharides (CPS) with heterobifunctional polyethylene glycol (PEG) of different length (2, 5 and 10â¯kDa) as linkers. The physiochemical properties of the CPS-PEG-HBc conjugate vaccines were fully characterized. The TEM, DLS, native agarose gel electrophoresis, and HPLC analyses all confirmed the successful conjugation. As compared to plain CPS and the physical mixture of CPS and HBc, the immunization with the conjugate vaccines can generate about 10 times increase in CPS specific IgG titers with a significant boosting effect. HBc conjugation induced a shift to a Th1 cellular immune type response, as assessed by the increased IgG2a subclass production. In addition, vaccination of the conjugate vaccines elicited much enhanced avidity functional antibody and long-lasting immunological memory. IgG titers elicited by CPS-P2k-HBc, CPS-P5k-HBc and CPS-P10k-HBc at week 18 maintained 38.1%, 17.9% and 33.3% of their peak values. All these results demonstrated that HBc VLPs can be used as potential carrier protein to develop polysaccharide conjugate vaccines effective in eliciting long-lasting and strong cellular immune response.
Subject(s)
Drug Carriers/administration & dosage , Hepatitis B Core Antigens/administration & dosage , Immunity, Cellular , Meningococcal Vaccines/immunology , Neisseria meningitidis, Serogroup C/immunology , Polysaccharides, Bacterial/immunology , Vaccines, Virus-Like Particle/immunology , Animals , Antibodies, Bacterial/blood , Female , Immunoglobulin G/blood , Meningitis, Meningococcal/prevention & control , Meningococcal Vaccines/administration & dosage , Mice, Inbred BALB C , Th1 Cells/immunology , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Vaccines, Virus-Like Particle/administration & dosageABSTRACT
Hepatitis B virus (HBV) infection is a global public health problem. T helper (Th)1associated cytokines are involved in HBV clearance during acute and persistent infection. In our previous study, it was demonstrated that lentiviral vectors encoding ubiquitinated hepatitis B core antigen (LVUbHBcAg) effectively transduced dendritic cells (DCs) to induce maturation, which promoted T cell polarization to Th1 and generated HBcAgspecific cytotoxic T lymphocytes (CTLs) ex vivo. In the present study, HBV transgenic mice were immunized with LVUbHBcAgtransduced DCs and HBcAgspecific immune responses were evaluated. Cytokine expression was analyzed by ELISA. T lymphocyte proliferation was detected with a Cell Counting Kit8 assay and HBcAgspecific CTL activity was determined using a lactate dehydrogenase release assay. The expression levels of p38mitogenactivated protein kinase (p38MAPK), phosphorylated (p)p38MAPK, cJun Nterminal kinase (JNK) and pJNK were detected by western blot analysis. The results demonstrated that LVUbHBcAgtransduced DCs significantly increased the Th1/Th2 cytokine ratio, and effectively reduced the levels of serum hepatitis B surface antigen (HBsAg), HBV DNA, and liver HBsAg and HBcAg. Furthermore, the LVUbHBcAgtransduced DCs upregulated the expression of pP38MAPK and pJNK in T lymphocytes. In conclusion, the present study indicated that LVUbHBcAgtransduced DCs generated predominant Th1 responses and enhanced CTL activity in HBV transgenic mice. Activation of the P38MAPK/JNK signaling pathway may be involved in this induction.
Subject(s)
Dendritic Cells/immunology , Hepatitis B Core Antigens/immunology , Hepatitis B virus/immunology , Hepatitis B/immunology , Animals , Cell Differentiation/immunology , Dendritic Cells/transplantation , Enzyme-Linked Immunosorbent Assay , Genetic Vectors/immunology , Hepatitis B/genetics , Hepatitis B/therapy , Hepatitis B/virology , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Core Antigens/genetics , Hepatitis B virus/pathogenicity , Humans , Immunization , Lentivirus/genetics , Lentivirus/immunology , MAP Kinase Kinase 4/genetics , Mice , Mice, Transgenic , Signal Transduction/immunology , Th1 Cells/immunology , Ubiquitination , p38 Mitogen-Activated Protein Kinases/geneticsABSTRACT
Skin cancer or cutaneous carcinoma, is a pre-eminent global public health problem with no signs of plateauing in its incidence. As the most common treatments for skin cancer, surgical resection inevitably damages a patient's appearance, and chemotherapy has many side effects. Thus, the main aim of this study was to screen for a cell penetrating peptide (CPP) for the development of a targeting vector for skin cancer. In this study, we identified a CPP with the sequence NRPDSAQFWLHH from a phage displayed peptide library. This CPP targeted the human squamous carcinoma A431 cells through an interaction with the epidermal growth factor receptor (EGFr). Methyl-ß-cyclodextrin (MßCD) and chlorpromazine hydrochloride (CPZ) inhibited the internalisation of the CPP into the A431 cells, suggesting the peptide entered the cells via clathrin-dependent endocytosis. The CPP displayed on hepatitis B virus-like nanoparticles (VLNPs) via the nanoglue successfully delivered the nanoparticles into A431 cells. The present study demonstrated that the novel CPP can serve as a ligand to target and deliver VLNPs into skin cancer cells.
Subject(s)
Cell-Penetrating Peptides/metabolism , Drug Delivery Systems , Hepatitis B Core Antigens/administration & dosage , Nanoparticles/metabolism , Vaccines, Virus-Like Particle/administration & dosage , Amino Acid Sequence , Cell Line, Tumor , Cell-Penetrating Peptides/chemistry , Endocytosis , ErbB Receptors/metabolism , Hepatitis B/metabolism , Hepatitis B Core Antigens/metabolism , Humans , Nanoparticles/chemistry , Peptide Library , Skin Neoplasms/metabolism , Vaccines, Virus-Like Particle/metabolismABSTRACT
Therapeutic vaccines represent a unique approach to hepatitis B virus (HBV) treatment and have the potential to induce long-term control of infection. This study explored the immune responses of rhesus macaques to novel vaccines comprising the S, PreS1, and Core antigens of the HBV that showed promise as prophylactic and therapeutic approaches in a mouse model. The tested vaccines included two DNA vaccines (pVRC-SS1, pVRC-CS1), an HBV particle subunit (HBSS1) vaccine and the recombinant vaccinia virus- (RVJ-) based vaccines (RVJSS1 and RVJCS1) in which SS1 containing S (1-223â¯aa) and PreS1 (21-47â¯aa), CS1 containing Core (1-144â¯aa) and PreS1 (1-42â¯aa). The humoral immunity and cell-mediated immunity (CMI) induced by vaccines comprising the S, PreS1, and Core antigens of HBV were investigated in a longitudinal study that continued up to 98â¯weeks after the firstvaccination. In rhesus macaques, anti-PreS1 antibody was induced more rapidly than anti-S or anti-Core antibody after DNA vaccination. The antibody and cell-mediated immune responses against S, PreS1, and C were significantly enhanced in macaques boosted with RVJSS1 and RVJCS1, whereas the cell-mediated response to C was most robust and durable. The immune response to S, PreS1, and C was restored by HBSS1 boosting and detected in macaques until weeks 74 and 98 after the first vaccination. Additionally, robust neutralizing activity was detected at week 52. In conclusion, novel HBV vaccine candidates, especially those used for therapeutic applications should incorporate the PreS1 and Core antigens.
Subject(s)
Antigens, Viral/immunology , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B virus/immunology , Animals , Antigens, Viral/administration & dosage , Female , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Vaccines/administration & dosage , Immunity, Cellular , Immunity, Humoral , Immunization Schedule , Longitudinal Studies , Macaca mulatta , Male , Time Factors , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunologyABSTRACT
Background: Vaccination with synthetic long peptides (SLP) is a promising new treatment strategy for chronic hepatitis B virus (CHB). SLP can induce broad T-cell responses for all HLA types. Here we investigated the ability of a prototype HBV-core (HBc)-sequence-derived SLP to boost HBV-specific T cells in CHB patients ex vivo. Methods: HBc-SLP was used to assess cross-presentation by monocyte-derived dendritic cells (moDC) and BDCA1+ blood myeloid DC (mDC) to engineered HBV-specific CD8+ T cells. Autologous SLP-loaded and toll-like receptor (TLR)-stimulated DC were used to activate patient HBc-specific CD8+ and CD4+ T cells. Results: HBV-SLP was cross-presented by moDC, which was further enhanced by adjuvants. Patient-derived SLP-loaded moDC significantly increased autologous HBcAg18-27-specific CD8+ T cells and CD4+ T cells ex vivo. HBV-specific T cells were functional as they synthesized tumor necrosis factor-alpha and interferon-gamma. In 6/7 of patients blockade of PD-L1 further increased SLP effects. Also, importantly, patient-derived BDCA1+ mDC cross-presented and activated autologous T-cell responses ex vivo. Conclusions: As a proof of concept, we showed a prototype HBc-SLP can boost T-cell responses in patients ex vivo. These results pave the way for the development of a therapeutic SLP-based vaccine to induce effective HBV-specific adaptive immune responses in CHB patients.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Hepatitis B Core Antigens/administration & dosage , Hepatitis B, Chronic/therapy , Immunotherapy/methods , Adult , Antigen Presentation , Dendritic Cells/immunology , Female , Hepatitis B Core Antigens/genetics , Hepatitis B Core Antigens/immunology , Humans , Interferon-gamma/metabolism , Male , Middle Aged , Models, Biological , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Hepatocellular carcinoma (HCC) is a deadly human malignant tumor that is among the most common cancers in the world, especially in Asia. Hepatitis B virus (HBV) infection has been well established as a high risk factor for hepatic malignance. Studies have shown that Pokemon is a master oncogene for HCC growth, suggesting it as an ideal therapeutic target. However, efficient delivery system is still lacking for Pokemon targeting treatment. In this study, we used core proteins of HBV, which is modified with RGD peptides, to construct a biomimetic vector for the delivery of Pokemon siRNAs (namely, RGD-HBc-Pokemon siRNA). Quantitative PCR and Western blot assays revealed that RGD-HBc-Pokemon siRNA possessed the highest efficiency of Pokemon suppression in HCC cells. In vitro experiments further indicated that RGD-HBc-Pokemon-siRNA exerted a higher tumor suppressor activity on HCC cell lines, evidenced by reduced proliferation and attenuated invasiveness, than Pokemon-siRNA or RGD-HBc alone. Finally, animal studies demonstrated that RGD-HBc-Pokemon siRNA suppressed the growth of HCC xenografts in mice by a greater extent than Pokemon-siRNA or RGD-HBc alone. Based on the above results, Pokemon siRNA delivery mediated by RGD-modified HBV core protein was shown to be an effective strategy of HCC gene therapy.
Subject(s)
Carcinoma, Hepatocellular/therapy , DNA-Binding Proteins/antagonists & inhibitors , Hepatitis B Core Antigens/administration & dosage , Liver Neoplasms/therapy , RNA, Small Interfering/administration & dosage , Transcription Factors/antagonists & inhibitors , Viral Core Proteins/administration & dosage , Animals , Carcinoma, Hepatocellular/genetics , Cell Line , Hepatitis B/physiopathology , Heterografts , Humans , Liver Neoplasms/genetics , Male , MiceABSTRACT
The prevalence of hepatitis B virus (HBV) infection in Asia and sub-Sahara Africa is alarming. With quarter of a billion people chronically infected worldwide and at risk of developing liver cancer, the need for a prophylactic or therapeutic vaccination approach that can effectively induce protective responses against the different genotypes of HBV is more important than ever. Such a strategy will require both the induction of a strong antigen-specific immune response and the subsequent deployment of immune response towards the liver. Here, we assessed the ability of a synthetic DNA vaccine encoding a recombinant consensus plasmid from genotype A through E of the HBV core antigen (HBcAg), to drive immunity in the liver. Intramuscular vaccination induced both strong antigen-specific T cell and high titer antibody responses systematically and in the liver. Furthermore, immunized mice showed strong cytotoxic responses that eliminate adoptively transferred HBV-coated target cells. Importantly, vaccine-induced immune responses provided protection from HBcAg plasmid-based liver transfection in a hydrodynamic liver transfection model. These data provide important insight into the generation of peripheral immune responses that are recruited to the liver-an approach that can be beneficial in the search for vaccines or immune-therapies to liver disease.
Subject(s)
DNA, Viral/immunology , Hepatitis B Core Antigens/immunology , Hepatitis B Vaccines/immunology , Liver/immunology , Vaccines, DNA/immunology , Administration, Intranasal , Animals , Antibody Formation , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/virology , DNA, Viral/administration & dosage , DNA, Viral/genetics , Enzyme-Linked Immunospot Assay , Female , Genes, Viral , Genotype , Hepatitis B/immunology , Hepatitis B/therapy , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Core Antigens/genetics , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/genetics , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatocytes/immunology , Hepatocytes/virology , Liver/virology , Mice , Mice, Inbred BALB C , Plasmids/metabolism , Transfection , Vaccination/methods , Vaccines, DNA/administration & dosageABSTRACT
Induction of hepatitis B virus (HBV)-specific cytotoxic T cells by therapeutic immunization may be a strategy to treat chronic hepatitis B. In the HBV animal model, woodchucks, the application of DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen (WHcAg) in combination with antivirals led to the prolonged control of viral replication. However, it became clear that the use of more potent vaccines is required to overcome WHV persistence. Therefore, we asked whether stronger and more functional T-cell responses could be achieved using the modified vaccines and an optimized prime-boost vaccination regimen. We developed a new DNA plasmid (pCGWHc) and recombinant adenoviruses (AdVs) showing high expression levels of WHcAg. Mice vaccinated with the improved plasmid pCGWHc elicited a stronger WHcAg-specific CD8(+) T-cell response than with the previously used vaccines. Using multicolor flow cytometry and an in vivo cytotoxicity assay, we showed that immunization in a DNA prime-AdV boost regimen resulted in an even more vigorous and functional T-cell response than immunization with the new plasmid alone. Immunization of naïve woodchucks with pCGWHc plasmid or AdVs induced a significant WHcAg-specific degranulation response prior to the challenge, this response had not been previously detected. Consistently, this response led to a rapid control of infection after the challenge. Our results demonstrate that high antigen expression levels and the DNA prime-AdV boost immunization improved the T-cell response in mice and induced significant T-cell responses in woodchucks. Therefore, this new vaccination strategy may be a candidate for a therapeutic vaccine against chronic HBV infection.
Subject(s)
Adenoviridae/immunology , Hepatitis B Core Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B virus/immunology , Hepatitis B/immunology , T-Lymphocytes/immunology , Vaccines, DNA/immunology , Adenoviridae/genetics , Animals , Cells, Cultured , Disease Models, Animal , Female , Hepatitis B/virology , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Core Antigens/genetics , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/genetics , Hepatitis B virus/genetics , Humans , Immunization, Secondary , Marmota , Mice , Mice, Inbred C57BL , Vaccines, DNA/administration & dosage , Vaccines, DNA/geneticsABSTRACT
The hepatitis B core (HBc) protein has been used successfully in numerous experiments as a carrier for heterologous peptides. Folding and capsid formation of the chimeric proteins is not always achieved easily. In silico analyses were performed to provide further comprehension of the feasibility for predicting successful capsid formation. In contrast to previous work, we show that common in silico predictions do not ensure assembly into particles. We included new considerations regarding capsid formation of HBc fusion proteins. Not only the primary sequence and the length of the inserts seem important, also the rigidity, the distance between the N and the C-terminus and the presence of cysteines, which could form disulphide bonds, could influence proper capsid formation. Furthermore, new conformational insights were formulated when linkers were added to create extra flexibility of the chimeric particles. Different hypotheses were suggested to clarify the obtained results. To this extent, the addition of glycine-rich linkers could lower high rigidity of the insert, removal of the strain of the core protein or ease interaction between the HBc and the insert. Finally, we observed specific changes in capsid formation properties when longer linkers were used. These findings have not been reported before in this and other virus-like particle carriers. In this study, we also propose a new high-yield purification protocol for fusion proteins to be used in vaccination experiments with the carrier protein or in comparative studies of particulate or non-particulate HBc fusion proteins.
Subject(s)
Hepatitis B Core Antigens/administration & dosage , Hepatitis B Vaccines/administration & dosage , Amino Acid Sequence , DNA/chemistry , Electrophoresis, Polyacrylamide Gel , Genetic Vectors , Humans , Molecular Sequence Data , Protein FoldingABSTRACT
Successful immunotherapy of chronic hepatitis B virus (HBV) infection is expected to be characterized by enhanced activation of immune responses. Combining the specificity of hepatitis B core antigen (HBcAg) cytotoxic T lymphocyte (CTL) epitope, the cell-penetrating property of human immunodeficiency virus-1 (HIV)-Tat peptide, and the adjuvanticity of CpG oligodeoxynucleotides (CpG ODNs) may elicit strong immune responses and therapeutic effects in HBV infection. We synthesized a fusion peptide containing HBcAg18-27 CTL epitope and HIV-Tat(49-57) peptide. The fusion peptide was intramuscularly injected to HBV transgenic mice with CpG ODN as adjuvant at 2-week intervals three times. The percentages of CD3(+), CD4(+) and CD8(+) cells in spleen lymphocytes and the levels of circulating interferon (IFN)-gamma and interleukin (IL)-2 were determined for the evaluation of immune responses and the levels of serum HBV DNA and the expression of hepatitis B surface antigen (HBsAg) and HBcAg in liver tissue were determined for the assessment of therapeutic effects. Our results showed that the synthesized fusion peptide adjuvanted with CpG ODN could induce significant increase of the percentages of CD3(+), CD4(+) and CD8(+) cells and the levels of IFN-gamma and IL-2, indicating the strong immune responses, and reduced HBV DNA levels and decreased expression of HBsAg and HBcAg in liver tissue, suggesting the therapeutic effects. Collectively, our study supports that HBcAg18-27 CTL epitope fused to HIV-Tat(49-57) peptide adjuvanted with CpG ODN may be a promising strategy for immunotherapy of chronic HBV infection.
Subject(s)
Epitopes, T-Lymphocyte/metabolism , HIV/immunology , Hepatitis B Core Antigens/metabolism , Hepatitis B virus/immunology , Hepatitis B, Chronic/therapy , Immunotherapy , Recombinant Fusion Proteins/metabolism , Spleen/drug effects , tat Gene Products, Human Immunodeficiency Virus/metabolism , Adjuvants, Immunologic/administration & dosage , Animals , Cells, Cultured , DNA/administration & dosage , Epitopes, T-Lymphocyte/administration & dosage , Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/immunology , Female , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Core Antigens/genetics , Hepatitis B Core Antigens/immunology , Hepatitis B virus/growth & development , Hepatitis B virus/pathogenicity , Hepatitis B, Chronic/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Oligodeoxyribonucleotides , Protein Engineering , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Spleen/immunology , Spleen/metabolism , Spleen/pathology , tat Gene Products, Human Immunodeficiency Virus/administration & dosage , tat Gene Products, Human Immunodeficiency Virus/genetics , tat Gene Products, Human Immunodeficiency Virus/immunologyABSTRACT
The hepatitis B virus core (HBc) virus-like particle (VLP) is known as one of the most immunogenic antigens and carrier vehicles in different immunization strategies. Recent findings are suggesting the potential of the HBc VLPs as an oral immunogen. Here, we focus on the induction of serum humoral responses by oral administration of HBc VLPs in preparations substantially free of lipopolysaccharide and immunomodulating encapsidated RNA. The full-length HBc antigen was used, because the C-terminal arginine-rich tail may contribute to the immunogenicity of the antigen as the region is involved in cell surface heparan sulfate binding and internalization of the protein. Serum antibody levels and isotypes were determined following oral administration of the HBc VLPs with the perspective of using the HBc VLP as an immunostimulatory and carrier molecule for epitopes of blood-borne diseases in oral immunization vaccination strategies. Following oral administration of the HBc VLP preparations to mice, a strong serum humoral response was induced with mainly immunoglobulin G2a (IgG2a) antibodies, pointing toward a Th1 response which is essential in the control of intracellular pathogens. Intraperitoneal immunization with the HBc VLP induced a stronger, mixed Th1/Th2 response. Finally, a comparison was made with the induced serum humoral response following oral administration of the recombinant cholera toxin B pentamer, a commonly used oral immunogen. These immunizations, in contrast, induced predominantly antibodies of the IgG1 isotype, indicative of a Th2 response. These data suggest that the HBc VLP can be an interesting carrier molecule in oral vaccine development.
Subject(s)
Antibodies, Bacterial/immunology , Cholera Toxin/administration & dosage , Hepatitis B Antibodies/immunology , Hepatitis B Core Antigens/administration & dosage , Administration, Oral , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/classification , Antigens, Viral/immunology , Cholera Toxin/genetics , Cholera Toxin/immunology , Hepatitis B Antibodies/blood , Hepatitis B Core Antigens/genetics , Hepatitis B Core Antigens/immunology , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Immunization , Mice , Mice, Inbred BALB C , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/metabolismABSTRACT
Chimeric HBcAg proteins carrying epitopes from surface hepatitis B virus (HBV) protein (regions 137-147 a.o. HBsAg, 27-37 a.a. region preS1 and 131-145 a.a. region preS2) have been early constructed. This paper presents the data of an investigation of a humoral immune response in mice immunized with obtained by chimeric HBcAg proteins. The findings suggest that the chimeric HBcAg proteins carrying the epitopes of surface HBV protein are able to induce an immune response to both inserted epitopes and carrying protein (HBcAg). Immunization with a mixture of chimeric proteins taken in equivalent quantities induces the synthesis of antibodies to hybrid proteins. The use of aluminum hydroxide considerably enhances a humoral immune response during immunization with chimeric bovine proteins.
Subject(s)
Epitopes/immunology , Hepatitis B Antibodies/blood , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B/immunology , Immunization , Adjuvants, Immunologic/administration & dosage , Aluminum Hydroxide/administration & dosage , Aluminum Hydroxide/immunology , Animals , Epitopes/administration & dosage , Epitopes/genetics , Hepatitis B/blood , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Core Antigens/genetics , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/genetics , Immunization Schedule , Injections, Intramuscular , Mice , Mice, Inbred BALB C , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunology , Vaccines, Synthetic/immunologyABSTRACT
The hepatitis B virus (HBV) core antigen (HBcAg) is a potent immunogen in animal models and humans and has been used as a carrier for several antigens; however, the mucosal immunogenicity of HBcAg has been poorly studied. In this study, we explored the immunogenicity and the immunoenhancing effect elicited by two different variants of the recombinant complete nucleocapside of HBV in mice by intranasal route. For this purpose, we used as co-administered antigen, the HBV surface protein (HBsAg) and the antibody response in sera was evaluated after each dose. To analyze the specificity of the generated antibody response, the recognition of lineal epitopes was evaluated on a cellulose membrane bearing 12 mer peptides covering the HBcAg sequence. The obtained results evidenced that the intranasal immunogenicity of both variants of HBcAg was similar and high, developing early responses of IgG. The immunoenhancing effect on the HBsAg-specific antibody response was also similar for both variants. The results of the recognition of lineal epitopes study evidenced a similar recognition pattern to all sera and vaginal lavages samples generated by the immunization of mice with the two variants of HBcAg, and also similar to a pool of human anti-HBcAg positive sera samples.
Subject(s)
Hepatitis B Core Antigens/immunology , Hepatitis B Vaccines/immunology , Administration, Intranasal , Animals , Antibodies, Viral/blood , Epitopes/immunology , Female , Hepatitis B/immunology , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Surface Antigens/administration & dosage , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Humans , Immunoglobulin G/blood , Mice , Ticks/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Vagina/immunologyABSTRACT
The type of immune response developed against the hepatitis B virus (HBV) is crucial in determining the outcome of the disease. The protective effects of vaccine-induced antibody responses against subsequent exposure to HBV are well-established. After the establishment of chronic HBV infection, cell-mediated immune response is curative while humoral response is detrimental. A therapeutic vaccine that could switch the type of response could lead to disease resolution. Hepatitis B core antigen (HBcAg)(129-140) has been identified as a Th2-biased peptide in H-2(b) mice when it is administered along with complete Freund's adjuvant (CFA). We formulated HBcAg(129-140) along with monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles. Naive mice immunized with the nanoparticle formulation developed a strong Th1-type response while mice immunized with the control formulation of CFA and peptide did not. We then primed mice with CFA and peptide to establish a Th2-type immune response before administering the nanoparticle formulation. Mice receiving the nanoparticle formulation being primed with CFA still developed a strong Th1-type response, while mice that received incomplete Freund's adjuvant and peptide instead of nanoparticles did not. The ability of PLGA nanoparticles to alter the type of immune response elicited by a peptide, even in the context of an ongoing immune response, makes PLGA nanoparticles a strong candidate for the formulation of therapeutic vaccines.
Subject(s)
Hepatitis B Core Antigens/administration & dosage , Peptide Fragments/immunology , Th1 Cells/immunology , Amino Acid Sequence , Animals , Female , Immunization , Interferon-gamma/biosynthesis , Lactic Acid/administration & dosage , Lipid A/administration & dosage , Lipid A/analogs & derivatives , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Nanostructures , Polyglycolic Acid/administration & dosage , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers/administration & dosage , T-Lymphocytes/immunology , Th2 Cells/immunologyABSTRACT
The non-cytopathic hepatitis B virus (HBV) can induce chronic infections characterized by weak and limited T cell responses against the virus. The factors contributing to the failure to clear HBV and subsequent development of chronic HBV infections are not clearly understood, but a strong interferon-gamma (IFN-gamma) response by CD4+ T cells against the nucleocapsid hepatitis B core antigen (HBcAg) of the virus appears to be important for viral clearance. The present study documents depressed numbers of CD4+ T cells secreting IFN-gamma and interleukin-2 (IL-2) in enzyme-linked immunospot assay (ELISPOT) assays restimulated for 24 hr with antigen following both primary and secondary immunizations of mice with recombinant hepatitis B core antigen (rHBcAg). The kinetics of these responses showed that the depression occurred following a peak response and lasted approximately 2 weeks before returning to the previous peak levels. The depression was abrogated by depletion of CD25+ cells prior to culture in the ELISPOT assay, suggesting inhibition by regulatory T cells. This inhibition of IFN-gamma and IL-2 production was also reversed by in vitro restimulation of the test cells for 48 hr rather than 24 hr in the assay. No such transient, reversible inhibition was detected in the production of IL-5, a Th2-type cytokine. The inhibition in cytokine production did not appear to correlate with the number of antibody-secreting cells or the isotypes produced. This delay by regulatory T cells of Th1-type cytokine production could contribute to viral persistence in chronic HBV infection by interfering with the critical role IFN-gamma plays in protection against viral infections.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Hepatitis B Core Antigens/immunology , Interferon-gamma/immunology , T-Lymphocytes, Regulatory/immunology , Animals , Antibodies, Viral/immunology , Biomarkers/analysis , Enzyme-Linked Immunosorbent Assay/methods , Hepatitis B Core Antigens/administration & dosage , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/prevention & control , Immunization , Immunoblotting , Interleukin-2/analysis , Interleukin-2/immunology , Interleukin-5/analysis , Interleukin-5/immunology , Lymphocyte Depletion , Mice , Mice, Inbred C3H , Receptors, Interleukin-2/immunology , Recombinant Proteins/administration & dosage , Recombinant Proteins/immunology , Time FactorsABSTRACT
BACKGROUND: In mice, highly repetitive antigens, such as those present on bacterial or viral surfaces, efficiently cross-link B-cell receptors and therefore induce strong IgG responses. In this study we covalently coupled a synthetic 16-amino-acid sequence of the allergen Der p 1 to a virus-like particle derived from the bacteriophage Qbeta (Qbeta-Der p 1). OBJECTIVE: We evaluated the safety and immunogenicity of Qbeta-Der p 1 in human subjects and compared different doses and routes of immunization. METHODS: In a phase I trial 24 healthy volunteers were randomly assigned to one of 4 treatment groups. Group 1 received 50 microg of Qbeta-Der p 1 intramuscularly, group 2 received 50 microg of Qbeta-Der p 1 subcutaneously, group 3 received 10 microg of Qbeta-Der p 1 intramuscularly, and group 4 received 10 microg of Qbeta-Der p 1 subcutaneously. Boosting immunizations with 10 microg were given after 1 and 3 months. Antibody titers were measured after 1, 3, 4, 6, 12, and 18 months. RESULTS: The vaccine Qbeta-Der p 1 was well tolerated. Significant IgG responses were observed 4 weeks after a single injection. Individuals receiving 50 microg of the vaccine had significantly higher IgG titers than those vaccinated with 10 microg. However, the route of immunization (subcutaneous vs intramuscular) had no effect. In the 50-microg dose group, strong antibody responses against Der p 1 with average titers of 1:2000 were obtained. CONCLUSION: Vaccination with a peptide antigen covalently coupled to highly repetitive virus-like particles represents an adjuvant-free means of rapidly inducing high antibody titers in human subjects. CLINICAL IMPLICATIONS: Allergens coupled to virus-like particles can be used to enhance the efficiency of allergen-specific immunotherapy.
Subject(s)
Allolevivirus/immunology , Antibodies, Viral/biosynthesis , Antigens, Dermatophagoides/immunology , Peptide Fragments/immunology , Pyroglyphidae/immunology , Viral Vaccines/immunology , Virion/immunology , Adolescent , Adult , Amino Acid Sequence , Animals , Antigens, Dermatophagoides/administration & dosage , Arthropod Proteins , Cysteine Endopeptidases , Female , Hepatitis B Core Antigens/administration & dosage , Hepatitis B Core Antigens/adverse effects , Hepatitis B Core Antigens/immunology , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/adverse effects , Hepatitis B Vaccines/immunology , Humans , Immunoglobulin G/biosynthesis , Male , Middle Aged , Molecular Sequence Data , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Vaccines, Combined/administration & dosage , Vaccines, Combined/adverse effects , Vaccines, Combined/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/adverse effectsABSTRACT
Antigen specific immune responses that occur early after antigen exposure differ from those that are present late in the response. The present study focused on detecting changes in production of IFNgamma by CD4+ T cells over time during chronic antigen exposure. (C3HxCB17)F1 mice were primed with recombinant hepatitis B core antigen (rHBcAg) in incomplete Freund's adjuvant to allow persistent antigen exposure. To assay the CD4+ T cell response to HBcAg, splenocytes from immunized mice were restimulated with rHBcAg for 24 or 48 h in vitro and tested for IFNgamma and IL-5 secreting cells by ELISPOT. Results showed that early after antigen exposure (7 days for primary and 3 days for secondary exposures), the maximal number of IFNgamma secreting cells was detected in the ELISPOT after 24 h of restimulation. However, late after antigen exposure (28 days for primary and 14 days for secondary exposures), the maximum number of IFNgamma secreting cells was not detected until 48 h of restimulation in this assay. This delay in IFNgamma production was related to the availability of IL-2, since addition of IL-2 allowed the delayed cells from late responses to develop peak IFNgamma production in vitro by 24 h, equivalent to that of cells from early responses. This IL-2 dependent delay occurred in Th1-type IFNgamma responses but not in Th2-type IL-5 responses. These observations indicate that, when detecting IFNgamma secreting cells it is important to screen responses at different times of restimulation or in the presence and absence of IL-2 to ensure optimal detection. This approach should prove critical, particularly when evaluating patients with chronic infections and in determining the effectiveness of vaccines since these deal with both early and late responses.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Enzyme-Linked Immunosorbent Assay/methods , Interferon-gamma/biosynthesis , Animals , Hepatitis B Core Antigens/administration & dosage , Humans , Immunization , Interleukin-2/administration & dosage , Interleukin-5/biosynthesis , Mice , Mice, Inbred C3H , Th1 Cells/immunology , Th2 Cells/immunology , Time FactorsABSTRACT
Several adjuvants have been described and tested in humans. However, the aluminum-based adjuvants remain the most widely used component in vaccines today. Emerging data suggest that aluminum phosphate and aluminum hydroxide adjuvants do not promote a strong commitment to the helper T cell type 2 (Th2) pathway when they are coadministered with some Th1 adjuvants. In this regard, subtle differences between both aluminum-based adjuvants have been demonstrated. We have previously shown that subcutaneous immunization, in aluminum phosphate, of a mixture comprising the surface and core antigens of hepatitis B virus (HBV) and the multiepitopic protein CR3 of human immunodeficiency virus type 1 elicits a CR3-specific Th1 immune response. In these experiments, the antigens were adjuvated at the same time. As the final selection of the best adjuvant should be based on experimental evidence, we asked whether aluminum hydroxide allows a better Th1 immune deviation than aluminum phosphate. We also studied several ways to mix the antigens and the impact on CR3-specific interferon (IFN)-gamma secretion. Our findings indicate that aluminum hydroxide allows better Th1 immunodeviation than aluminum phosphate adjuvant for the mixture of HBV antigens and CR3. In addition, CR3-specific IFN-gamma secretion of the various formulations tested was the same irrespective of the order in which the antigens were combined.